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The antiphospholipid antibodies (aPL), namely, the lupus anticoagulant and the anticardiolipin antibodies, are a family of autoantibodies
directed predominantly against negatively charged phospholipids. Many studies have confirmed that patients with these antibodies are
prone to repeated episodes of thrombosis, fetal losses, and thrombocytopenia. The association of aPL with these clinical events has been
termed the antiphospholipid syndrome. Several skin lesions have been found in patients with this syndrome, including livedo reticularis,
livedoid vasculitis, thrombophlebitis, cutaneous infarctions and gangrene of digits, ulcerations, lesions resembling vasculitis (nodules,
macules), cutaneous necrosis/infarctions, subungual splinter hemorrhages, and, less commonly, discoid lupus and Degos’ disease
(malignant atrophic papulosis). In this article, we review the main immunologic and clinical aspects of this syndrome with special emphasis
on the dermatologic features. J Invest Dermatol 100:21S–27S, 1993
The antiphospholipid antibodies (aPL), namely, those responsible for the
lupus anticoagulant (LA) tests and the anticardiolipin antibodies (aCL), are a
heterogenous group of autoantibodies directed predominantly against
negatively charged phospholipids. Patients with these antibodies are prone
to repeated episodes of venous and/ or arterial thrombosis, recurrent fetal loss,
and thrombocytopenia [1,2]. The association of aPL with these clinical events
has been termed the antiphospholipid syndrome (APS) [3].
A variety of skin lesions have been found in patients with this syndrome
and the dermatologic features of this condition have recently been reviewed
[4–6]. We shall focus not only on the skin lesions of the APS but also on the
main immunologic and clinical aspects that may be of interest to
dermatologists.
PREVALENCE
The presence of aPL has been mainly demonstrated in sera of patients with
systemic lupus erythematosus (SLE), with a prevalence ranging between 20%
and 50% [1,2]. Additionally, they have less frequently been found in other
connective tissue diseases [7], as well as in drug induced, malignant, and
infectious disorders [2] (Table I).
Positive aPL titers have also been found in up to 30% of women with
idiopathic repeated abortion [8,9] and in up to 19% of patients with venous or
arterial thrombosis attending a routine anticoagulation clinic and who do not
suffer from SLE or any other well-delineated autoimmune disorder [10]. These
patients may be considered to be suffering from a ‘‘primary’’ APS.
METHODS OF DETECTION
There are two major groups of methods for detecting aPL. The first group relies on
the inhibition of in vitro blood coagulation caused by the LA and includes several
clotting tests with different sensitivities (Table II). The second is based on solid-
phase immunoassays employing purified phospholipids as antigens, the most
commonly used being cardiolipin. A radioimmunoassay (RIA) for the detection of
aCL was first described in 1983 [11]. Subsequently, several solid phase enzyme-
linked immunosorbent assays (ELISA) were developed.
The aCL assays, unlike the LA tests, are more sensitive, have less observer error,
and may be performed using stored sera. However, a relatively wide variation of
results still occurs on a single sample, both on inter-assays and between different
laboratories performing the test. In an attempt to achieve better concordance of
results, a semi-quantitative manner of reporting results was recommended by the
second standardization workshop conducted in 1988. It was then suggested that
sample results should be reported as ‘‘high,’’ ‘‘medium,’’ or ‘‘low’’ positive [12]
(Table III).
IMMUNOLOGY
It has recently become evident that the aPL are a heterogeneous group of
autoantibodies with different characteristics. As only a minority of patients with
aPL develop thrombotic complications, possible explanations for the differ-
ences between ‘‘innocent’’ and ‘‘pathogenic’’ antibodies may be attributed to
isotypic diversity as well as to differences in the level, binding specificity,
avidity, idiotype, and associated genetic and environmental factors. These
immunologic aspects have recently been reviewed in depth [13].
MECHANISMS OF ACTION
The exact mechanism by which aPL cause the clinical manifestations of the
APS is still unknown. In fact, whether these antibodies are the main cause of
the clinical manifestations related to the vascular occlusive events or simply
‘‘epiphenomena’’ accompanying more basic underlying immunologic dis-
turbances such as occurs with other autoantibody systems is still unclear.
Because phospholipids are essential constituents of cell membranes and
also play an integral part in the major hemostatic pathways, most efforts to
elucidate the mechanisms of thrombosis in patients with aPL have been based
on the effects of these antibodies on endothelial cell and platelet function as
well as on the fibrinolytic system.
In addition, the requirement for a serum ‘‘cofactor’’ (b2-glycoprotein I)
that enhances the binding of aPL to phospholipids has been recently
demonstrated [14]. There is strong evidence that aPL from patients with
autoimmune disorders are directed against a complex antigen of which
b2-glycoprotein I is an essential component. Affinity-purified aPL from these
patients fail to bind to cardiolipin coated on ELISA wells unless exogenous
b2-glycoprotein I is added. In contrast, aPL fractions from patients
with infections, including syphilis and human immunodeficiency virus
(HIV) infection, bind directly to the phospholipids in the absence of
b2-glycoprotein I.
This glycoprotein is well known to inhibit the intrinsic pathway of
coagulation, to act as an antiprothrombinase in vitro, to bind to activated
protein C, to interact with heparin, and to inhibit ADP-dependent platelet
aggregation. This raises the possibility that b2-glycoprotein I may bind to
platelets and could be the cellular epitope for aPL binding, thus predisposing
to platelet aggregation resulting in thrombotic events. Additionally, because
b2-glycoprotein I demonstrates homology with a number of complement
receptors and some cell-surface adhesions molecules, the possibility of cross-
reactivity with these structures represents an attractive alternative hypothesis.
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CLINICAL MANIFESTATIONS
The majority of clinical manifestations described as being associated with aPL
may be explained by the coexistence of vascular occlusions or thrombosis,
either of veins, arteries, or endocardium. It was originally thought that only
large vessels were affected. Deep vein thrombosis (occasionally superficial
thrombophlebitis) particularly affecting the veins of the lower limbs are the
commonest venous occlusions seen. Strokes, often preceded by transient
ischemic attacks, are the most frequent arterial events encountered.
However, it has recently become evident that small vessels might also be
involved. Therefore, many diverse clinical manifestations due to vascular
occlusions in the liver, adrenal glands, lungs, heart, kidney, eyes, etc., may
now be associated with the presence of aPL (Table IV). Other conditions,
where no definitive evidence of vascular occlusions has as yet been
confirmed, are less strongly associated (Table V).
On the other hand, recurrent fetal losses also occur in patients with the
APS. Several authors have found that fetal losses are associated with
thrombosis of the placental vessels and subsequent infarction resulting in
placental insufficiency, fetal growth retardation, and ultimately fetal loss.
Skin Manifestations A large variety of skin manifestations have been
described in patients with the APS (Table VI). The majority of them can be
explained by histopathologic evidence of vascular occlusions.
Livedo Reticularis: This is a violet discoloration of the skin that has a
reticulated pattern. It is caused by stagnation of blood in dilated superficial
capillaries and venules and implies pathologic changes in deeper larger
vessels. It affects the skin of the thighs, shins, forearms, and trunk less
frequently. Areas of normal skin are clearly demarcated from affected areas.
This lesion may occur as a reaction to cold in normal people, particularly
women. Additionally, it may be demonstrable in a variety of pathologic states
characterized either by hyperviscosity or in conditions where the primary
pathology is in the arterioles, capillaries, or venules of the skin [15].
Interestingly, livedo reticularis is a common finding in connective tissue
diseases, particularly in SLE. Hughes, in 1983, first drew attention to the
association of this skin manifestation with aPL [16]. Several further studies
[17–20] confirmed this association.
Sneddon, an English dermatologist, in 1965 first drew attention to the
association of livedo reticularis with cerebrovascular accidents [21]. All six
patients reported were hypertensive and five were women. This association in
non-SLE patients became known as Sneddon’s syndrome (livedo-cerebrovas-
cular syndrome) and many other reports of the condition subsequently
appeared [22–24]. Endarteritis obliterans was demonstrated on biopsy in the
patients documented by Quimby and Perry [24] and Champion [22]. Jonas
et al [25] first reported an association between patients with Sneddon’s
syndrome and aPL and it is now evident that a proportion of non-SLE patients
presenting with this syndrome are examples of the ‘‘primary’’ APS [26,27].
Livedoid Vasculitis: Bard and Winkelman [28] in 1967 described
patients presenting with ‘‘atrophie blanche,’’ a disorder resulting from
Table I. Diseases in Which aPL Have Been Found
Autoimmune diseases
Systemic lupus erythematosus
Rheumatoid arthritis
Scleroderma
Dermatomyositis-Polymyositis
Sjo¨gren syndrome
Temporal arteritis/Polymyalgia rheumatica
Takayasu’s arteritis
Behcet’s disease
Autoimmune hemolytic anemia
Idiopathic thrombocytopenic purpura
Diabetes mellitus
Hashimoto’s thyroiditis
Myasthenia gravis
Drug-induced ‘‘lupus-like’’ syndromes
Cnlorpromazine
Procainamide
Hydralazine
Quinidine
Phenytoin
Sulphonamides
Infectious diseases
Bacterial (tuberculosis, leprosy, syphilis, Lyme disease, infective
endocarditis, Klebsiella infections)
Protozoan (Pneumocystis carinii, plasmodium)
Viral (AIDS, mononucleosis, hepatitis, rubella, parvovirus)
Hematologic diseases
Thrombotic thrombocytopenic purpura
Sickle cell disease
Polycythemia vera
Myelofibrosis
Monoclonal gammopathies
Von Willebrand’s disease
Malignant diseases
Hairy cell leukemia
Malignant lymphoma
Waldenstrom’s macroglobulinemia
Epithelial malignancies (lung, maxilla, prostate, esophagus, colon, cervix)
Hypernephroma
Thymoma
Other conditions
Renal failure undergoing dialysis
Table II. Clotting Tests to Detect LA
Partial thromboplastin time
Activated partial thromboplastin time
Kaolin clotting time
Dilute Russell viper venom time
Exner test
Table III. Semi-Quantitative Manner of Reporting aCL
Results
IgG aCL IgM aCL
High positive 480 GPL 450MPL
Medium positive 15–80 GPL 6–50 MPL
Low positive 5–15 GPL 3.5–6 MPL
Negative o5GPL o3.5 MPL
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non-inflammatory occlusions of dermal arterioles resulting in superficial
cutaneous ulceration and atrophic skin. Some patients with this condition
have demonstrated a defect in the fibrinolytic system with diminished release
of tissue plasminogen activator [29].
This results in microthrombosis with subsequent breakdown of skin.
Venous thrombosis, particularly affecting deep veins of the legs as well as
mesenteric vessels resulting in pulmonary emboli and bowel infarctions,
occurs in this condition. There has been speculation as to whether a ‘‘subset’’
of patients with this disorder and aPL can be identified. Among the original
patients described by Winkelman were six with connective tissue diseases
and in one, with SLE, LA was found.
Thrombophlebitis: In the recent large series of Alegre et al [5] from the
Mayo Clinic, 34% of 70 patients with LA and skin manifestations presented with
a thrombophlebitic syndrome consisting of edema and cutaneous erythema
affecting the lower leg, ankle, and calf. These changes were all consequent on
deep vein thrombosis or incompetence secondary to thrombosis.
Cutaneous Infarctions and Gangrene of Digits (Fig 1): Distal cutaneous
ischemic symptoms culminating in gangrene of digits resulting from arterial or
arteriolar occlusions have been described in several patients with aPL [5,30–34].
Gangrene in SLE may also be associated with vasculitis, cryoglobulinemia, or,
uncommonly, dissemminated intravascular coagulation. In some, the presence of
aPL may coexist with these other conditions. The exact relationship of the
presence of aPL coexisting with these pathologies is unclear at the present time.
Skin Ulceration (Fig 2): Johansson et al [35] in 1977 documented eight
patients with biologic false-positive tests for syphilis and LA who not only
presented with recurrent deep venous thromboses of the extremities but also with
painful superficial ‘‘star-like’’ ulcers around the ankles. Three patients had SLE.
The ulcers healed with white atrophic scars surrounded by a dark pigmented
halo. Recurrent purpuric lesions sometimes preceded the development of these
ulcers. Steroid therapy resulted in little therapeutic success, but the administration
Table IV. Main Occlusive Vascular Manifestations
Associated with aPL
Vessel Involved Clinical Manifestations
Veins
Limbs Thrombophlebitis
Liver
Large vessels Budd-Chiari syndrome, veno-occlusive disease
Small vessels Hepatomegaly, enzyme elevations
Adrenal glands Addison’s disease, hypoadrenalism
Lungs Pulmonary embolism, thromboembolic pulmonary
hypertension
Eyes Retinal vein thrombosis
Arteries
Limbs Ischemia, gangrene
Brain
Large vessels Stroke, transient ischemic attacks, Sneddon’s
syndrome
Small vessels Acute ischemic encephalopathy, multi-infarct
dementia
Heart
Large vessels Myocardial infarction
Small vessels
Acute Circulatory collapse, cardiac arrest
Chronic Cardiomyopathy, arrhythmia, bradycardia,
ventricular dyskinesia
Kidney
Large vessels Renal artery thrombosis
Small vessels Renal thrombotic microangiopathy
Liver Hepatic infarction, nodular regenerative
hyperplasia
Aorta
Arch vessels Aortic arch syndrome
Abdominal Mesenteric ischemia/infarction
Eyes Retinal artery and arteriolar thrombosis
Endocardium
Valves
Acute Vegetations, ‘‘pseudoinfective endocarditis’’
Chronic Valve dysfunction (regurgitation, stenosis),
cerebral embolism
Chambers Thrombus, ‘‘pseudotumour’’, cerebral embolism
Table V. Other Manifestations Possibly Associated
with aPL
Neurologic
Chorea
Transverse myelitis
Guillain-Barre´ syndrome
Psychosis
Bone
Avascular necrosis
Pulmonary
Non-thromboembolic pulmonary hypertension
Hepatic
Nodular regenerative hyperplasia
Hematologic
Thrombocytopenia
Hemolytic anemia
Evans’ syndrome
Neutropenia
Table VI. Cutaneous Manifestations Associated with
the aPL
I. Livedo reticularis
II. Livedoid vasculitis
III. Thrombophlebitis
IV. Cutaneous gangrene and necrosis of digits
V. Skin ulcerations
VI. Lesions resembling vasculitis (nodules, macules)
VII. Cutaneous necrosis/infarctions
VIII. Subungual splinter hemorrhages
IX. Discoid lupus
X. Degos’ disease (malignant atrophic papulosis)
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of anticoagulants seemed to limit the appearance of new lesions and thrombosis.
Histopathologically there was a marked proliferation of dermal capillaries.
Prominent endothelial cells with few inflammatory cells were evident. Thickened
and hyalinized walls were seen in large or medium-sized arterioles. Other similar
patients have been reported [5,6,34,36–39]. Some authorities have particularly
stressed the occurrence of this vascular proliferation termed ‘‘antiphospholipid
arterial vasculopathy’’ [40]. These painful ulcers are also seen in patients with
livedoid vasculitis [28].
Lesions Resembling Vasculitis (Nodules, Macules): Erythematous macules
on the fingertips were documented in a patient by Grob and Bonerandi [6].
Painful skin nodules in a patient with LA and Budd-Chiari syndrome were
reported by Farrant et al [41] and a decrease in size and pain in these nodules
with salicylate therapy documented by Asherson et al [42].
Cutaneous Necrosis/Infarctions (Fig 3): Superficial skin necrosis has been
reported by several investigators in patients having aPL [42–46]. An
association between the LA, coumadin skin necrosis, and cerebral venous
thrombosis was documented in two patients by Moreb and Kitchens [47].
Serum concentrations of free functional protein S were markedly depleted
because of excessive binding of protein S to C4b binding protein.
Subungual Splinter Hemorrhages: The occurrence of subungual splinter
hemorrhages in patients with aPL has only recently been recognized, although an
early report of a patient with this manifestation appeared in 1980 [48]. They have
been noted in patients with valve lesions in the absence of infective endocarditis,
with transient ischemic attacks [49,50], with the administration of oral
contraceptives or pregnancy [51], and with skin nodules, their appearance
coinciding with periods of increased pain in the nodules [42]. In another patient
with a ‘‘primary’’ APS, these subungual splinter hemorrhages appeared
coincident with the development of adrenal hypofunction consequent on
adrenal infarction after warfarin withdrawal [52]. This patient has subsequently
noted the reappearance of the splinter hemorrhages coincident with periods of
inadequate warfarinization and unstable coagulation control.
Discoid Lupus: aPL have been reported as occurring in patients with
discoid lupus without any manifestations of the APS [53]. On rare occasions,
patients with the APS may present lesions of discoid lupus without any
clinical or serologic manifestation of systemic disease [54].
Degos’ Disease (Malignant Atrophic Papulosis): Degos’ disease is a
multisystem vasculopathy with widespread thromboses affecting the skin,
central nervous system, and alimentary tract. Death normally occurs from
multiple cerebral or bowel infarctions [55]. Painless skin lesions, generally
small yellowish papules, are usually evident over the trunk mainly. Skin
biopsy reveals a total absence of inflammatory cells. A patient with this
condition, LA, and elevated aCL levels was documented by Englert et al [56].
The ‘‘Primary’’ Antiphospholipid Syndrome First conceptualized by Asherson
in 1988 [57], several series of paients have been documented detailing the
major clinical and serologic characteristics of the syndrome (Table VII)
[58–61]. Essentially, these patients present features of any patient with an APS,
e.g., thrombosis (venous and/or arterial), recurrent fetal losses, and/or
thrombo-cytopenia, but without SLE or any other well-defined disease. A
follow up longer than 5 years is recommended in order to rule out the
subsequent development of SLE. Many of these patients are male.
Some of these patients may, however, have very few of the clinical
manifestations of SLE or other connective tissue disorders. The clear separation of
this group of patients and those with SLE and ‘‘lupus-like’’ disease (‘‘probable’’
SLE) is important [59]. Patients with the ‘‘primary’’ APS essentially do not have
any of the ‘‘flares’’ (fever, arthralgias, myalgias), polyserositis, or immune
complex type nephritis seen in patients with SLE and ‘‘lupus-like’’ disease. They
do not usually have other features closely associated with SLE, such as Raynaud’s
phenomenon, alopecia, mouth ulcers, or butterfly rashes, but they may,
however, demonstrate vasculitic skin rashes. Serologically, the antinuclear
antibody level may be negative or low positive. Antibodies to dsDNA, estimated
by the Crithidia or Farr assays, are usually negative. However, in some patients,
presumably in those more closely related to SLE, low-affinity anti-dsDNA
antibodies may be demonstrable by ELISA. Antibodies to ENA are consistently
absent. Other immunologic disturbances such as rheumatoid factor, cryoglobu-
linemia or immune complexes may also be present. A number of patients may
demonstrate a low C4 level.
The Catastrophic Antiphospholipid Syndrome A minority of patients with
aPL may unusually develop an acute and catastrophic APS characterized
Figure 1. Necrosis of digits in hand (a) and foot (b).
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by vascular occlusions involving multiple organs. Ten such patients have
been recently documented and reviewed in the literature [60]. These patients
have in common the following.
a) Clinical evidence of multiple organ involvement (three or more): severe
renal dysfunction often accompanied by accelerated or malignant
hypertension; central nervous system symptomatology, heralded by
behavior disturbances, but ending in disturbances of consciousness such
as stupor and evidence of focal vascular disturbances, e.g., hemiparesis;
respiratory difficulties such as the clinical and radiologic picture of adult
respiratory distress syndrome (ARDS); skin manifestations such as livedo
reticularis, acrocyanosis, or ischemic ulcerations and gangrene; or other
organ failure due to multiple fibrin thrombi occluding small vessels, e.g.,
myocardial arteriolar thromboses, adrenal vessel occlusion, hepatic
infarction and, rarely, ischemic bowel ulceration.
b) Histopathologic evidence of multiple large and small vessel occlusion.
c) Serologic confirmation of the presence of aPL, usually in high titer.
Other features of the APS, such as thrombocytopenia, are also frequent. If the
patient has SLE, activity of the disease is usually mild or absent, with low
levels of antibodies to dsDNA.
This condition usually appears suddenly in a well-controlled patient, but
sometimes an upper respiratory tract infection or drug administration may
appear to precipitate the disease.
The catastrophic APS may superficially resemble other vasculo-
pathies, such as thrombotic thrombocytopenic purpura (TTP), dissemminated
intravascular coagulation (DIC), systemic thromboembolism, and systemic
vasculitis. The presence of extensive purpura, fluctuating neurologic
signs, and hemolytic anemia may assist in the differentiation of TTP, but
clearly there may be many similarities. The diagnosis of DIC depends to
a large extent on the presence of elevated fibrin split products as well
as thrombocytopenia. DIC is very rarely associated with aPL, although
several patients with SLE have developed this complication. Diagnosis
of the other two conditions may be difficult due to similarity of laboratory
markers.
Figure 2. Skin ulceration. Figure 3. Cutaneous necrosis.
Table VII. Criteria for Classification of the Primary
APS
Clinical Laboratory Conditions
Venous
thrombosis
IgG aCL
(moderate/
high levels)
i. Patients with the syndrome should
have at least one clinical plus one
laboratory finding during their disease.
Arterial
thrombosis
IgM aCL
(moderate/
high levels)
ii. aPL test must be positive on at least
two occasions more than 3 months
apart.
Recurrent
fetal loss
Positive
LA test
iii. A follow up longer than 2 years is
now considered mandatory to rule
out SLE and other autoimmune
disorders.
Thrombo-
cytopenia
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TREATMENT
An approach to the management of patients with aPL, who essentially present
with features common to other hypercoagulable states, could be to proceed as
in patients with known risk factors for the development of vascular
occlusions. This implies, firstly, attempting to eliminate the aPL, and,
secondly, the appropriate use of antiaggregant, anticoagulant, and fibrinolytic
drugs, following indications previously established for prophylaxis and
therapy of occlusive venous and arterial disease.
Elimination of the aPL Although energetic immunosuppression, e.g., with
‘‘pulse’’ cyclophosphamide, plasmapheresis, and gammaglobulin infusions,
are sometimes effective in reducing elevated antibody levels, there is usually
a rapid rebound to pretreatment levels shortly after discontinuation of the
therapy. Therefore, prophylaxis and therapy should not primarily be directed
at effectively reducing these antibody levels and the use of immunotherapy is
generally not indicated, unless required for the treatment of the underlying
condition, e.g., SLE, or in acute life-threatening situations.
However, energetic attempts should be made to avoid or treat any other
associated risk factors—e.g., antihypertensives, cholesterol-lowering agents,
treatment of active nephritis, avoidance of smoking or sedentarism, etc. Care
should be also taken with the administration of oral contraceptives in patients
with aPL. There is some evidence that their administration may result in
complications such as vascular occlusions or chorea in some.
Prophylaxis of Occlusive Vascular Complications In some trials within the
general population, the long-term use of aspirin has proved useful in the
prevention of arterial occlusions, mainly of coronary vessels. Therefore,
there may be a case for the prophylactic treatment of individuals with high
levels of IgG aCL or persistent LA activity with antiaggregants, especially in
those with added risk factors. These include low-dose salicylates and
antimalarials.
On the other hand, prophylaxis of venous thrombosis is required
particularly for patients undergoing surgical procedures or requiring long
stays in bed, or during the puerperium. In the general population, the use of
low-dose subcutaneous heparin (10,000–15,000 units daily) is recommended
in those circumstances. However, some patients with aPL may show some
resistance to these doses, as in other hypercoagulable states, and this dosage
may be insufficient in the prevention of thrombosis. It is therefore suggested
that higher-dose subcutaneous heparin (25,000 units daily) or intravenous
heparin (40,000 units daily) be administered.
Treatment of Occlusive Vascular Complications Experience in the treatment
of patients with aPL and vascular complications is short and based mainly on
retrospective studies. Until adequate prospective and controlled studies
become available, the same procedures as apply to the general population
with thrombosis should be followed. However, three special considerations
must be emphasized with respect to anticoagulation.
i) Because of the tendency to recurrence, patients require anticoagulation
on a long-term basis, and probably for life.
ii) Warfarin resistance has been encountered in several of these patients,
who may require up to 20mg/d of warfarin in order to achieve an
international normalized ratio (INR) within a therapeutic range—the INR
in patients with aPL should be kept at levels between 3 and 4.
iii) Because of the not uncommon finding of fluctuating levels of the INR,
frequent and regular visits to anticoagulation clinics must be recom-
mended, as well as instruction of patients and medical personnel as to
the dangers of noncompliance.
Treatment of the Catastrophic APS This depends on the early recognition of
the syndrome as well as the early administration of effective anticoagulation,
plasmapheresis, and, perhaps, ‘‘pulse’’ steroids and immunosuppression.
Concomitant hypertension and renal failure also require effective treatment.
Prevention of Fetal Losses A recent case-control study by Infante-Rivard et al
[61] has shown that the presence of aPL is not a risk factor for fetal loss in
pregnant women who have had no previous spontaneous fetal loss. Therefore,
the finding of these antibodies in a pregnant woman in the absence of a
previous history of spontaneous abortion is not an indication for treatment. In
those pregnant women with previous fetal losses or miscarriages, several
therapeutic approaches have been proposed, including subcutaneous
heparin, steroids, azathioprine, etc. However, most authors agree that low-
dose (50–100mg daily) aspirin, administered from the beginning of pregnancy
until a few days before delivery, has proved useful and safe in an acceptable
number of women with aPL. However, some experts recommend moderate
doses of steroids added to the aspirin if aPL level suddenly rises. In addition,
close monitoring of pregnancy with doppler technique, in order to detect
placental vascular insufficiency, and early delivery with the first signs of fetal
distress are mandatory. If the patient is receiving warfarin because of previous
thrombotic complications, this should be changed to subcutaneous heparin.
Patients with poor obstetric histories should additionally receive subcuta-
neous heparin (10,000 iu twice daily) for the duration of the pregnancy
according to some authorities.
Treatment of Thrombocytopenia Thrombocytopenia associated to aPL is
usually mild and does not require intervention. However, in a minority of
cases it can be severe and refractory to prednisone therapy. Low-dose aspirin
has proved useful in some cases, but its administration may not be without
risk, especially in patients with less than 20,000 platelets/mm3. In these cases,
immunosuppressive therapy, i.e., azathioprine, or danazol, may be effective.
In contrast, splenectomy should be considered with caution in patients with
aPL, due to the increased thromboembolic risk related to post-splenectomy
thrombocytosis. Splenic irradiation might be considered as an alternative.
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